BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9093729)

  • 1. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere).
    Hilkens PH; Verweij J; Vecht CJ; Stoter G; van den Bent MJ
    Ann Oncol; 1997 Feb; 8(2):187-90. PubMed ID: 9093729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral neuropathy secondary to docetaxel (Taxotere).
    New PZ; Jackson CE; Rinaldi D; Burris H; Barohn RJ
    Neurology; 1996 Jan; 46(1):108-11. PubMed ID: 8559355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lhermitte's sign following chemotherapy with docetaxel.
    van den Bent MJ; Hilkens PH; Sillevis Smitt PA; van Raaij-van den Aarssen VJ; Bontenbal M; Verweij J
    Neurology; 1998 Feb; 50(2):563-4. PubMed ID: 9484402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral neurotoxicity induced by docetaxel.
    Hilkens PH; Verweij J; Stoter G; Vecht CJ; van Putten WL; van den Bent MJ
    Neurology; 1996 Jan; 46(1):104-8. PubMed ID: 8559354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel neuropathy: a distal axonopathy.
    Fazio R; Quattrini A; Bolognesi A; Bordogna G; Villa E; Previtali S; Canal N; Nemni R
    Acta Neuropathol; 1999 Dec; 98(6):651-3. PubMed ID: 10603043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motor neuropathy due to docetaxel and paclitaxel.
    Freilich RJ; Balmaceda C; Seidman AD; Rubin M; DeAngelis LM
    Neurology; 1996 Jul; 47(1):115-8. PubMed ID: 8710063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
    Hilkens PH; Pronk LC; Verweij J; Vecht CJ; van Putten WL; van den Bent MJ
    Br J Cancer; 1997; 75(3):417-22. PubMed ID: 9020489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
    Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
    J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer.
    Chan YN; Jheng YW; Wang PJ; Chen CY; Lin MW; Wang YJ
    Clin J Oncol Nurs; 2019 Oct; 23(5):494-501. PubMed ID: 31538967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel.
    Rose PG; Smrekar M
    Gynecol Oncol; 2003 Nov; 91(2):423-5. PubMed ID: 14599877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats.
    Persohn E; Canta A; Schoepfer S; Traebert M; Mueller L; Gilardini A; Galbiati S; Nicolini G; Scuteri A; Lanzani F; Giussani G; Cavaletti G
    Eur J Cancer; 2005 Jul; 41(10):1460-6. PubMed ID: 15913989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.
    Pronk LC; Hilkens PH; van den Bent MJ; van Putten WL; Stoter G; Verweij J
    Anticancer Drugs; 1998 Oct; 9(9):759-64. PubMed ID: 9840720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group.
    van Hoesel QG; Verweij J; Catimel G; Clavel M; Kerbrat P; van Oosterom AT; Kerger J; Tursz T; van Glabbeke M; van Pottelsberghe C
    Ann Oncol; 1994 Jul; 5(6):539-42. PubMed ID: 7918126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect.
    Esmaeli B; Valero V; Ahmadi MA; Booser D
    Ophthalmology; 2001 May; 108(5):994-5. PubMed ID: 11320034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere).
    Skolnick CA; Doughman DJ
    Eye Contact Lens; 2003 Apr; 29(2):134-5. PubMed ID: 12695719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal use of docetaxel (Taxotere): maximizing its potential.
    Burris HA
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():25-8. PubMed ID: 8862707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel neuropathy.
    Pace A; Bove L; Pietrangeli A; Innocenti P; Jandolo B
    Neurology; 1996 Aug; 47(2):615. PubMed ID: 8757066
    [No Abstract]   [Full Text] [Related]  

  • 18. Docetaxel neuropathy.
    Apfel SC
    Neurology; 1996 Jan; 46(1):2-3. PubMed ID: 8559375
    [No Abstract]   [Full Text] [Related]  

  • 19. Docetaxel and autonomic cardiovascular control in anthracycline treated breast cancer patients.
    Ekholm E; Rantanen V; Bergman M; Vesalainen R; Antila K; Salminen E
    Anticancer Res; 2000; 20(3B):2045-8. PubMed ID: 10928149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
    Moon C; Verschraegen CF; Bevers M; Freedman R; Kudelka AP; Kavanagh JJ
    Anticancer Drugs; 2000 Aug; 11(7):565-8. PubMed ID: 11036959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.